Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. News
  7. Summary
    GSK   GB0009252882

GSK PLC

(GSK)
  Report
Delayed London Stock Exchange  -  11:39 2022-06-24 am EDT
1754.00 GBX   +2.00%
06/24European Stocks Join Global Rally, Closes Week in the Green
MT
06/24SECTOR UPDATE : Health Care Stocks Edge Higher Premarket Friday
MT
06/24European shares mark strong end to nervous week
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

S&P Maintains GSK's Ratings, Stable Outlook on Expected Post-Demerger Recovery

05/18/2022 | 11:24pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about GSK PLC
06/24European Stocks Join Global Rally, Closes Week in the Green
MT
06/24SECTOR UPDATE : Health Care Stocks Edge Higher Premarket Friday
MT
06/24European shares mark strong end to nervous week
RE
06/24Sanofi, GSK variant-specific COVID shot found effective against Omicron
RE
06/24Sanofi, GSK COVID-19 Bivalent Vaccine Candidate Shows 72% Efficacy Against Omicron in P..
MT
06/24Sanofi, GSK Target COVID-19 Vaccine Availability in Late-2022 After New Positive Late-s..
MT
06/24Sanofi-GSK's COVID-19 Jab 72% Effective Against Omicron Variant in Late-stage Study
MT
06/24Sanofi says COVID-19 vaccine candidate yields positive trial data
RE
06/24GSK : Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19..
PU
06/24GSK Says Sanofi-GSK First To Report Successful Efficacy Study Against Omicron With COVI..
RE
More news
Analyst Recommendations on GSK PLC
More recommendations
Financials
Sales 2022 36 045 M 44 302 M 44 302 M
Net income 2022 5 278 M 6 487 M 6 487 M
Net Debt 2022 17 490 M 21 497 M 21 497 M
P/E ratio 2022 16,2x
Yield 2022 2,98%
Capitalization 88 868 M 109 B 109 B
EV / Sales 2022 2,95x
EV / Sales 2023 2,81x
Nbr of Employees 90 096
Free-Float 93,6%
Chart GSK PLC
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 1 756,20 GBX
Average target price 1 868,86 GBX
Spread / Average Target 6,41%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Hal V. Barron Executive Director & Chief Scientific Officer
Jon Ellis VP & Head-Technology Business Development
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC9.17%109 224
JOHNSON & JOHNSON5.02%462 443
ELI LILLY AND COMPANY17.88%276 070
PFIZER, INC.-15.17%275 327
ABBVIE INC.12.51%260 755
ROCHE HOLDING AG-19.20%259 627